- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07855939
Long-term Iron Absorption and Loss in Women
Long-term Iron Absorption and Loss in Overweight/Obese Thai Middle-aged Women
Obese people typically have chronic low-grade inflammation. Based on short-term studies, this inflammation could affect the absorption, utilization, storage, and mobilization of iron, and individuals with inflammation might develop iron deficiency (ID) and anemia when inadequacy of iron intake is presented. The double burden of malnutrition is nowadays emerging as a major public health concern in many countries, including Thailand. Understanding the association of chronic inflammation among people with overweight or obesity (OW/OB) with long-term iron absorption and loss is important for developing appropriate policies and programs to promote iron balance and, consequently, optimal iron status and health outcomes. Since previous reports among Thai women showed a high prevalence of OW/OB and anemia, this study will be conducted to determine the long-term iron absorption and loss among OW/OB free-living women using the iron isotope dilution method.
Visão geral do estudo
Status
Condições
Descrição detalhada
- Research Objective To study iron absorption, loss, and long-term iron gain in overweight or obese middle-aged Thai women compared with normal-weight middle-aged Thai women.
- Research Methodology 2.1 Study design: This study is a longitudinal study comparing long-term iron absorption and loss between overweight or obese middle-aged Thai women and normal-weight middle-aged Thai women.
2.2 Study population: The study population consists of 64 women aged 40-50 years, divided into two groups: 32 overweight or obese women, and 32 normal-weight women.
2.3 Research Procedures 2.3.1 Before data collection: The research protocol is submitted for approval to the Central Institutional Review Board, Mahidol University. All data collectors will be trained prior to fieldwork. Upon receiving ethical approval, recruitment posters will be used to invite participants.
Screening process:
-
Interested individuals meeting preliminary eligibility criteria will be informed about study details, sign informed consent, and schedule the first visit for screening and blood collection.
-
Visit 1 (Screening):
- Collect demographic and health history, measure weight, height, and body composition.
- Collect 5 mL blood sample for Hb, SF, CRP, AGP, and hemoglobin typing.
- Perform urine pregnancy test.
- Administer one 400 mg albendazole tablet to prevent parasitic infection.
Iron isotope administration and follow-up:
2.3.2 Eligible participants will return within 1-2 weeks for the second visit.
Visit 2 (Month 0; M0):
Participants will consume a 15 mg ⁵⁷Fe isotope solution followed by 100 mg vitamin C drink, then fast for 3 hours.
A snack (plain yogurt and water) will be provided 1.5 hours after ingestion. A 24-hour dietary recall and semi-quantitative food frequency questionnaire (FFQ) will be conducted, with two additional 24-hour recalls by phone (2 weekdays and 1 weekend day).
Participants will then enter a 1-year equilibration period, recording illness and menstrual data monthly. The research team will monitor via LINE or email.
Visit 3 (Month 9; M9):
Collect fasting blood (5 mL) for Hb, glucose, HbA1c, and lipid profile; measure weight, BP, and conduct 24-hour recall (plus two by phone).
Visit 4 (After 1 year; WK0):
Collect fasting blood (10 mL) for Hb, SF, TfR, CRP, AGP, erythrocyte isotopic enrichment.
Measure weight, body composition, pregnancy test, and dietary recalls (3 days) and FFQ.
Visits 5-7 (WK8, WK16, WK24):
For eligible participants, repeat blood tests (7 mL) for Hb, SF, TfR, CRP, AGP, isotopic enrichment, anthropometry, pregnancy test, 3-day dietary recalls, and FFQ.
2.4 Research Instruments
-
General information and medical history questionnaire, 24-hour dietary recall, and FFQ.
-
Illness and menstrual record forms.
-
Anthropometry and clinical measures:
- Weight: InBody digital scale
- Height: Harpenden stadiometer
- Body composition: Bioelectrical Impedance Analyzer (BIA; InBody)
- Blood pressure: Omron digital sphygmomanometer
-
Laboratory analyses:
- Hb: Complete Blood Count (CBC) using flow cytometry
- SF, TfR, CRP, AGP: ELISA (SFa calculated from SF, CRP, AGP)
- Hemoglobin typing: Capillary electrophoresis
- Fasting glucose: Enzymatic method
- HbA1c: Turbidimetric inhibition immunoassay
- Lipids: Enzymatic colorimetric and homogeneous methods
- Iron isotopes: Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 2.5 Data Analysis Nutrient intake (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated using INMUCAL software.
Dietary patterns will be analyzed using Principal Component Analysis (PCA).
The average iron absorption (Fe_abs) over the study period will be calculated as:
Feabs=kabs×FetotalFe_{abs} = k_{abs} \times Fe_{total}Feabs=kabs×Fetotal where Fe_total is the total body iron at the midpoint estimated from the regression of Fe_total over time, and k_abs is the fractional iron absorption rate derived from the slope of the regression line of ln(⁵⁷Fe) vs. time.
Average iron loss (Fe_loss) is calculated similarly:
Feloss=kloss×FetotalFe_{loss} = k_{loss} \times Fe_{total}Feloss=kloss×Fetotal
Iron gain (Fe_gain) is calculated as:
Fegain=Feabs-FelossFe_{gain} = Fe_{abs} - Fe_{loss}Fegain=Feabs-Feloss Differences between groups in general characteristics, biochemical parameters, and iron absorption/loss slopes will be tested using Independent t-test or Mann-Whitney U-test, as appropriate.
A Linear Mixed-Effects Model will be used to analyze group differences in longitudinal changes of iron absorption, loss, and gain.
Statistical significance will be set at p < 0.05.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Tippawan Pongcharoen, Ph.D.
- Número de telefone: +66813749901
- E-mail: tippawan.pon@mahidol.ac.th
Estude backup de contato
- Nome: Aree Prachansuwan, Ph.D.
- Número de telefone: +66890060602
Locais de estudo
-
-
-
Nakhon Pathom, Tailândia, 73170
- Recrutamento
- Institute of Nutrition
-
Contato:
- Tippawan Pongcharoen, Ph.D.
- Número de telefone: 0813749901
- E-mail: tippawan.pon@mahidol.ac.th
-
Contato:
- Aree Prachansuwan, Ph.D.
- Número de telefone: +890060602
- E-mail: aree.prc@mahidol.ac.th
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
The study population will consist of 64 women aged 40-50 years, divided into two groups: 32 participants who are overweight or obese, and 32 participants with normal weight.
Descrição
Inclusion Criteria:
-
Normal weight group
- Aged 40-50 years
- Normal weight (BMI 18.5-22.9 kg/m²)
- Hb ≥12.0 g/dL and inflammation-adjusted SFa <50.0 µg/L
- CRP <5.0 mg/L
- Normal hemoglobin typing
- Plans to reside in the study area for >2 years
-
Overweight/obese group
- Aged 40-50 years
- Overweight or obese [Body Mass Index (BMI) ≥25.0 kg/m²] - the BMI cut-off follows the agreement of countries under the Coordinated Research Project (CRP) E43038 "Using the iron isotope dilution technique to assess the influence of inflammation on long-term iron absorption and loss," supported by the IAEA
- Hemoglobin (Hb) ≥12.0 g/dL and inflammation-adjusted serum ferritin (SFa) <50.0 µg/L
- C-reactive protein (CRP) between 5.0-25.0 mg/L
- Normal hemoglobin typing
- Plans to reside in the study area for >2 years
Exclusion Criteria:
-
Normal weight group
- Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure
- Having metabolic NCDs (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization
- Pregnant, breastfeeding, or planning pregnancy during the study
- Chronic infectious disease (e.g., tuberculosis, AIDS)
- Regular use of anti-inflammatory or other medications (except contraceptives and acne medication)
- Taking vitamin or mineral supplements during or within two weeks prior to the study
- Participating in a weight-loss program
- Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling)
- Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment
- Heavy menstrual bleeding (>80 mL/day, calculated from menstrual record)
-
Overweight/obese group
- Obesity class II (BMI ≥35.0 kg/m²) with high health risk
- Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure
- Having metabolic noncommunicable diseases (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization
- Pregnant, breastfeeding, or planning pregnancy during the study
- Chronic infectious disease (e.g., tuberculosis, AIDS)
- Regular use of anti-inflammatory or other medications (except contraceptives and acne medication)
- Taking vitamin or mineral supplements during or within two weeks prior to the study
- Participating in a weight-loss program
- Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling)
- Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment
- Heavy menstrual bleeding (>80 mL/day, calculated from menstrual record)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Normal weight
BMI 18.5-22.9 kg/m2 |
|
Overweight or obesity
BMI 25-35 kg/m2 |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean long-term iron absorption (Fe abs)
Prazo: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24).
|
Calculated over the duration of the study as follows: Fe abs = k abs x Fe total Where Fe total is the total body iron at the midpoint, calculated from the linear regression of Fe total versus time across each measurement point; and k abs is the fraction of total body iron absorbed per unit of time (derived from the slope of the linear regression equation of ln 57 Fe versus time). 57 Fe isotope will be measured using Inductively Coupled Plasma Mass Spectrometry (ICP-MS). |
Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24).
|
|
Mean long-term iron loss (Fe loss)
Prazo: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
Calculated in the same manner as iron absorption: Fe loss = k loss x Fe total Where k loss is the fraction of total body iron lost per unit of time. |
Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
|
Iron gain (Fe gain)
Prazo: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
Calculated as net iron balance: Fe gain = Fe abs - Fe loss |
Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Weight (kg)
Prazo: Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
Weight will be measured in kg (to the nearest 0.1 kg) using an Inbody digital weighing scale. |
Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
|
Height (cm)
Prazo: Visit 1 (Screening)
|
Height will be measured to the mearest 0.1 cm using a Harpenden stadiometer. |
Visit 1 (Screening)
|
|
Body Mass Index (BMI, kg/m²)
Prazo: Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
BMI will be calculatedn body weight in kilograms divided by height in meters squared. |
Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
|
Body composition (fat mass)
Prazo: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
|
Body composition (fat mass) will be measured using the Bioelectrical Impedance Analyzer (BIA; InBody). |
Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
|
|
Nutrient intakes
Prazo: Visit 2 (Month 0), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
Nutrient intakes (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated from 3-day 24-hr dietary recalls using INMUCAL software. |
Visit 2 (Month 0), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
|
Dietary pattern
Prazo: Visit 2 (Month 0), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
|
Dietary patern from FFQ will be analyzed using the Principal Component Analysis (PCA) |
Visit 2 (Month 0), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
|
|
Hemoglobin (Hb, g/L)
Prazo: Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
Hb concentration will be assessed using flow cytometry |
Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
|
Serum ferritin (SF, µg/L)
Prazo: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
SF will be measured using Enzyme-linked immunosorbent assay (ELISA) |
Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
|
serum transferrin receptor (sTfR µg/L)
Prazo: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
sTfR will be assessed using ELISA |
Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
|
c-reactive protein (CRP, mg/L)
Prazo: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
CRP will measured using ELISA |
Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
|
alpha-1 acid glycoprotein (AGP, g/L)
Prazo: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
AGP will be measured using ELISA |
Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
|
|
Glycated hemoglobin (HbA1c, %)
Prazo: Visit 3 (Month 9)
|
HbA1c wil be measured by Turbidimetric inhibition immunoassay |
Visit 3 (Month 9)
|
|
Lipid profile
Prazo: Visit 3 (Month 9)
|
Lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) will be measured using Enzymatic colorimetric and homogeneous methods. |
Visit 3 (Month 9)
|
|
Blood pressure (BP, mmHg)
Prazo: Visit 3 (Month 9)
|
BP will be measured using Omron digital sphygmomanometer |
Visit 3 (Month 9)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Veronica LOPEZ TEROS, Ph.D., Internation Atomic Energy Agency
Publicações e links úteis
Publicações Gerais
- Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, Moretti D, Zimmermann MB. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017 Nov;4(11):e524-e533. doi: 10.1016/S2352-3026(17)30182-5. Epub 2017 Oct 9.
- International Atomic Energy Agency (IAEA). Assessment of iron bioavailability in humans using stable iron isotope techniques. IAEA Human Health Series No.21, Vienna 2021. Available at https://www-pub.iaea.org/MTCD/Publications/PDF/Pub1544_web.pdf.
- Speich C, Mitchikpe CES, Cercamondi CI, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Direct assessment of body iron balance in women with and without iron supplementation using a long-term isotope dilution method in Benin and Switzerland. Am J Clin Nutr. 2021 Jun 1;113(6):1657-1669. doi: 10.1093/ajcn/nqaa433.
- Zimmermann MB, Zeder C, Muthayya S, Winichagoon P, Chaouki N, Aeberli I, Hurrell RF. Adiposity in women and children from transition countries predicts decreased iron absorption, iron deficiency and a reduced response to iron fortification. Int J Obes (Lond). 2008 Jul;32(7):1098-104. doi: 10.1038/ijo.2008.43. Epub 2008 Apr 22.
- Luciani N, Brasse-Lagnel C, Poli M, Anty R, Lesueur C, Cormont M, Laquerriere A, Folope V, LeMarchand-Brustel Y, Gugenheim J, Gual P, Tran A, Bekri S. Hemojuvelin: a new link between obesity and iron homeostasis. Obesity (Silver Spring). 2011 Aug;19(8):1545-51. doi: 10.1038/oby.2011.12. Epub 2011 Feb 10.
- Cepeda-Lopez AC, Aeberli I, Zimmermann MB. Does obesity increase risk for iron deficiency? A review of the literature and the potential mechanisms. Int J Vitam Nutr Res. 2010 Oct;80(4-5):263-70. doi: 10.1024/0300-9831/a000033.
- Cepeda-Lopez AC, Osendarp SJ, Melse-Boonstra A, Aeberli I, Gonzalez-Salazar F, Feskens E, Villalpando S, Zimmermann MB. Sharply higher rates of iron deficiency in obese Mexican women and children are predicted by obesity-related inflammation rather than by differences in dietary iron intake. Am J Clin Nutr. 2011 May;93(5):975-83. doi: 10.3945/ajcn.110.005439. Epub 2011 Mar 16.
- Gonzalez-Dominguez A, Visiedo-Garcia FM, Dominguez-Riscart J, Gonzalez-Dominguez R, Mateos RM, Lechuga-Sancho AM. Iron Metabolism in Obesity and Metabolic Syndrome. Int J Mol Sci. 2020 Aug 1;21(15):5529. doi: 10.3390/ijms21155529.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- C00NU66050024
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
There has been ongoing discussion regarding collaboration on data analysis and publication among countries that have conducted studies supported by the International Atomic Energy Agency (IAEA).
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .